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Abstract
Background: Sensitivity to ischemia and its underlying mechanisms in type 2 diabetic hearts are
still largely unknown. Especially, correlation between reperfusion induced ventricular arrhythmia
and changes in intracellular pH has not been elucidated.
Methods and results: Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats at 16 and 32
weeks of age were used along with age-matched nondiabetic Long-Evans Tokushima Otsuka
(LETO) rats. Hearts from rats in these 4 groups were perfused in the working heart mode, thus
inducing whole heart ischemia. At 16 weeks of age, no differences in blood glucose levels or
incidence and duration of reperfusion arrhythmia were found between the strains. At 32 weeks of
age, both impaired glucose tolerance and obesity were observed in the OLETF rats. Further, the
duration of reperfusion-induced ventricular fibrillation (VF) was significantly longer in the OLETF
rats, while the pH level was significantly lower and proton contents were significantly higher in
coronary effluent during ischemia in those rats. Following treatment with troglitazone,
improvements in pH and proton level in coronary effluent during ischemia were observed, as was
the duration of reperfusion-induced VF in OLETF rats at 32 weeks of age.
Conclusion: The hearts of spontaneously diabetic OLETF rats were found to be more susceptible
to ischemic insult. Troglitazone treatment improved ischemic tolerance by improving glucose
metabolism in the myocardium of those rats.
Background
Diabetes mellitus (DM) accelerates changes in atheloscle-
rosis, which leads to an increase in both clinical incidence
of ischemic heart disease and mortality rate [1]. Further,
independent of coronary artery disease, type 2 DM has
direct adverse effects on the myocardium [2]. To elucidate
the mechanisms of these actions, recently, echocardio-
graphical study [3] or some whole heart perfusion experi-
ments using type 2 diabetic model rodents have been
performed. Alterations in energy metabolism in the myo-
cardium of type 2 diabetic rodents have been well investi-
gated [4-6], whereas ion homeostasis has been rarely
investigated [7] in ischemia-reperfusion study.
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Otsuka Long-Evans Tokushima Fatty (OLETF) strain is a
spontaneously type 2 DM model rat with diabetic compli-
cations [8] that shows late onset hyperglycemia at 18
weeks of age. In the present study, we induced ischemia in
perfused OLETF rat hearts in order to examine the changes
in pH and proton production, during and after ischemia,
as well as the incidence and duration of ventricular
arrhythmia after reperfusion. Furthermore, we observed if
improvement in diabetic state by troglitazone [9], a thia-
zolidinedione, acts to the ischemic injury in heart from
diabetic OLETF rat.
Methods
Experimental groups
The present study was undertaken in accordance with the
Animals (Scientific Procedures) Act 1986 and conforms
with the Guide for the Care and Use of Laboratory Ani-
mals published by US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
Male OLETF rats at 6 weeks of age, age-matched non-dia-
betic Long-Evans Tokushima Otsuka (LETO) rats [8] were
obtained from the Otsuka Pharmacology Laboratory
(Tokushima, Japan). All of these rats were maintained at
the Jikei University animal experiment center and were
kept under controlled temperatures (21 ± 2°C) with a 12-
hour artificial light and dark cycle. These rats were then
divided into 6 subgroups: OLETF at 16 weeks of age (16-
O, n = 8), LETO at 16 weeks of age (16-L, n = 8), OLETF at
32 weeks of age (32-O, n = 8), LETO at 32 weeks of age
(32-L, n = 8), OLETF at 32 weeks of age treated with trogl-
itazone (32-OT, n = 8), and LETO at 32 weeks of age
treated with troglitazone (32-LT, n = 7). Rat standard lab-
oratory chow (type MF, Oriental Yeast Co) with or with-
out troglitazone (0.2% vol/vol) was given ad libitium
from ages 24 to 32 weeks.
Body weights
The body weight (BW) was measured immediately before
each heart perfusion experiment.
Oral glucose tolerance test
The oral glucose tolerance test (OGTT) was performed in
all groups within a week before each perfusion experi-
ment. After 18 hours of fasting, glucose fluid (2 g/kg BW)
was administered using a gastric tube. Blood samples were
obtained via the tail vein at 3 time points: before the
administration of glucose fluid (pre), 60 minutes after
loading, and120 minutes after loading.
Heart perfusion and ischemia
Rats in all groups were anesthetized with sodium pento-
barbital (50 mg/kg, i.p. injection) and a thoracotomy was
performed after 18 hours of fasting. Blood samples were
obtained from the inferior vena cava for measurements of
glycohemoglobin A1c (HbA1c) levels and serum levels of
insulin. The hearts were quickly removed and then
immersed in ice-cold Krebs-Henseleit bicarbonate solu-
tion. The aorta and the pulmonary vein were cannulated,
and Langendorff's retrograde perfusion was initiated at
37°C and a hydrostatic pressure of 80 mmHg. After 10
min, Langendorff perfusion was switched to the physio-
logical perfusion, working heart mode by clamping the
aortic inflow line from the Langendorff reservoir, and
opening the left atrial inflow and aortic line. The afterload
was maintained at 60 mmHg of hydrostatic pressure and
the preload was maintained at 7 mmHg throughout the
experiment. Modified Krebs-Henseleit bicarbonate buffer
containing (in mmol) NaCl 118, KCl 4.7, NaHCO3 2.5,
CaCl2 2.5, MgSO4·H2O 1.2, EDTA 0.5, KH2PO4 1.2 and
glucose 11 (37°C, pH 7.4) bubbled with 95% O2and 5%
CO2 was used as the perfusion buffer. Subsequent to the 5
min control perfusion, whole heart ischemia (flow rate 5–
10%) was induced by the use of a one-way ball valve
which prevented retrograde perfusion during diastole and
the hearts were then perfused with electrical pacing (300
beats/min) for 10 min. After reperfusion, the pacing and
the ball valve action were stopped for an additional 20
min.
Hemodynamic measurements and analysis of the coronary 
effluent
The aortic flow was measured with an electromagnetic
flowmeter (Nihon-Koden MFV 2100, Tokyo). An 18-
gauge catheter was inserted via the left atrium into the left
ventricle to measure the left ventricular (LV) pressure, the
peak positive first derivative of LV pressure (LV +dP/dt)
and peak negative first derivative of LV pressure (LV -dP/
dt) with a polygraph system (Fukuda Denshi Co., Tokyo,
MIC 8600). An electrocardiogram (ECG) recorded from
an epicardium was monitored using carbon lead attached
to the surface of the heart. The coronary flow was collected
by a heart chamber at 5 min intervals throughout the
period of perfusion. Cardiac output was estimated as the
sum of the aortic and coronary flow.
The coronary effluent was collected from the pulmonary
artery and used for determination of venous PO2, PCO2,
HCO3 
- and pH levels with a blood gas analyzer (Corning
175, USA).
Arrhythmia study
ECG was continuously recorded on a recorder throughout
the experiment. The ECG data were retrospectively ana-
lyzed, in a blind manner, for the incidence, time to onset,
and duration of ventricular fibrillation (VF) during reper-
fusion. All analyses were carried out in accordance with
the Lambeth Conventions [10]. VF was defined as a signal
in which individual QRS deflections could no longer beCardiovascular Diabetology 2007, 6:17 http://www.cardiab.com/content/6/1/17
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distinguished from one another and the heart rate could
not be determined.
Biochemical analysis
The blood glucose level was measured in the whole blood
using glucose oxidase method. HbA1c was measured by
the latex method. The plasma insulin level was measured
using the enzyme-immunoassay insulin kits (Morinaga,
Tokyo Japan).
The proton production in coronary effluent was calcu-
lated from the PCO2 and HCO3 
- values as follows: [H+] (n
mol/l) = 24 × PCO2 (mmHg)/[HCO3 
-] (m mol/l)
Stastical analysis
Values are expressed as the mean ± standard error. The
data were analyzed using either Student's t-test for
unpaired data or analysis of variance followed by appro-
priate post-hoc test to locate differences between groups.
Binominal distributed variables, such as the incidence of
VF, were compared using the χ2 test for a 2 × n table, fol-
lowed by a sequence of 2 × 2χ2 tests with Yates's correc-
tion. A value of p < 0.05 was considered to be statistically
significant.
Results
Characteristics of OLETF and LETO rats
Body weight was significantly higher in 16-O compared
with that in 16-L, while 32-O seemed to be obese, with
body weight significantly higher as compared with 32-L
and 16-O. No significant differences were seen in body
weights among the groups based on troglitazone treat-
ment. The level of HbA1c showed no difference between
16-L and 16-O, however, that in 32-O was significantly
higher than that in 32-L. HbA1c in 32-OT was signifi-
cantly lower as compared with 32-O, while there was no
significant difference between 32-LT and 32-L. The
plasma glucose level in 16-O was higher than that in 16-L
before OGTT, however, there were no differences between
those 2 groups in regard to OGTT results. The level of
plasma glucose in 32-O showed a significantly higher
level than that in 32-L before and during OGTT, while a
significant improvement in plasma glucose level in 32-OT
was observed following treatment with troglitazone
before and in OGTT results. In contrast, troglitazone did
not have an affect on plasma glucose level in 32-LT. The
serum insulin level showed no significant difference
between 16-O and 16-L, however, that in 32-O tended to
be higher than that in 32-L (p= 0.08). Hyperinsulinemia
seen in 32-O improved slightly, as shown in 32-OT (p =
0.10), by treatment with troglitazone. These results are
shown in Table 1.
Basal cardiac function
In the perfused working hearts, there were no differences
in the heart rate, coronary flow, cardiac output, LV pres-
sure, and LV ± dP/dt between 16-O and 16-L. The effects
of aging in these parameters were not seen between 32-O
and 16-O, and between 32-L and 16-L. In addition, there
were no significant differences in these parameters
between 32-OT and 32-O, or between 32-LT and 32-L.
These results are shown in Table 2.
Reperfusion induced arrhythmia
Reperfusion induced arrhythmia VF occurred during the
early phase of reperfusin after ischemia. There were no sig-
nificant differences in the incidence of VF between OLETF
and age-matched LETO rats. The incidence of VF (Fig. 1A)
was 50% in both 16-O and 16-L, while that in 32-O was
100%, though it decreased (32-OT: 50%, p = 0.10) by
treatment with troglitazone. There was no significant dif-
ference in the duration of VF (Fig. 1B) between 16-O and
16-L. That in 32-O was significantly longer than in 32-L.
The duration of VF in 32-O was significantly shortened by
treatment with troglitazone, and that in 32-L was also sig-
nificantly shortened as compared with 32-LT.
Changes in pH of coronary effluent
In all groups, pH of the coronary effluent decreased dur-
ing ischemia and then recovered after ischemia. There
were no significant differences in pH values of coronary
effluent samples throughout the ischemia-reperfusion
Table 1: Characteristics of the LETO and OLETF rats in each groups
16-L 16-O 32-L 32-O 32-LT 32-OT
(n = 8) (n = 8) (n = 8) (n = 8) (n = 7) (n = 8)
Body Weight (g) 383.8 ± 8.9 468.8 ± 10.6 ** 460.8 ± 7.6 563.2 ± 15.2†† 465.0 ± 14.9 521.4 ± 21.5
HbA1c (%) 3.04 ± 0.07 3.18 ± 0.06 3.17 ± 0.07 4.45 ± 0.26†† 3.09 ± 0.13 3.52 ± 0.07#
Serum Insulin (ng/ml) 1.5 ± 2.3 2.4 ± 0.8 1.7 ± 0.9 3.3 ± 1.1 1.6 ± 0.6 1.8 ± 0.2
Plasma glucose in OGTT (mg/dl)
pre 86.6 ± 2.2 100.9 ± 4.1* 106.3 ± 3.7 122.3 ± 5.1† 95.8 ± 2.0 98.8 ± 3.9#
60 min 131.1 ± 4.1 157.1 ± 14.4 142.5 ± 4.1 310.7 ± 5.0†† 134.9 ± 1.7 225.6 ± 6.9##
120 min 102.6 ± 4.1 100.9 ± 1.9 101.9 ± 1.9 161.5 ± 4.8†† 95.1 ± 3.1 98.9 ± 4.3##
Values are the means ± SEM. HbA1c, glycohemoglobin A1c; OGTT, oral glucose tolerance test.
*p < 0.05 vs 16-L, **p < 0.01 vs 16-L, †p < 0.05 vs 32-L, ††p < 0.01 vs 32-L, #p < 0.05 vs 32-O, ## p < 0.01 vs 32-OCardiovascular Diabetology 2007, 6:17 http://www.cardiab.com/content/6/1/17
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protocol between 16-O and 16-L (Fig. 2A), however, pH
in 32-O was significantly lower than in 32-L at 9 minutes
during ischemia (Fig. 2B). The pH value in 32-LT did not
show a significant difference compared with that in 32-L
throughout the ischemia-reperfusion protocol (Fig. 3A),
though the decrease in pH was significantly suppressed in
32-OT as compared with 32-O at 5 and 9 minutes during
ischemia (Fig. 5B).
Changes in proton production in coronary effluent
Proton efflux increased during ischemia and recovered
after reperfusion in all groups. No significant difference
was observed between the proton efflux levels in 16-O
and 16-L (Fig. 4A), whereas that in 32-O was significantly
higher than that in 32-L at 5 and 9 minutes during
ischemia (Fig. 4B). No significant difference was observed
between 32-LT and in 32-L throughout the perfusion pro-
tocol (Fig. 5A), while the increase in proton efflux was sig-
nificantly suppressed in 32-OT as compared with 32-O at
5 and 9 minutes during ischemia (Fig. 5B).
Changes in pH of coronary effluent in LETO and OLETF rats  at 16 weeks of age (A) and 32 weeks of age (B) Figure 2
Changes in pH of coronary effluent in LETO and OLETF rats 
at 16 weeks of age (A) and 32 weeks of age (B). Closed cir-
cles show LETO rats, open circles show OLETF rats. * p < 
0.05 vs. LETO rats.
Table 2: Myocardial function before ischemia in each group.
16-L (n = 8) 16-O (n = 8) 32-L (n = 8) 32-O (n = 8) 32-LT (n = 7) 32-OT (n = 6)
HR (beats/min) 212.3 ± 13.2 202.5 ± 7.7 219.1 ± 7.7 202.8 ± 10.7 218.2 ± 5.6 201.0 ± 9.3
CF (ml/min) 16.0 ± 1.0 17.1 ± 1.0 19.5 ± 0.5 21.1 ± 0.8 21.2 ± 0.7 21.7 ± 0.4
CO (ml/min) 45.1 ± 3.5 52.9 ± 2.2 51.1 ± 3.0 50.4 ± 4.0 58.1 ± 2.7 51.0 ± 2.8
LVP (mmHg) 133.0 ± 3.0 142.8 ± 4.6 135.5 ± 4.9 134.1 ± 6.3 140.1 ± 1.9 130.7 ± 2.8
LV +dP/dt (mmHg/sec × 103) 2.6 ± 0.3 2.9 ± 0.2 4.0 ± 0.2 3.6 ± 0.2 4.1 ± 0.1 3.4 ± 0.1
LV -dP/dt (mmHg/sec × 103) 2.5 ± 0.2 2.5 ± 0.3 3.2 ± 0.3 2.8 ± 0.3 3.3 ± 0.3 3.0 ± 0.2
Values are mean SEM. HR, Heart rate; CF, Coronary flow; CO, Cardiac output; LVP, Left ventricular pressure; LV +dP/dt, Peak positive first 
derivative of left ventricular pressure; LV -dP/dt, Peak negative first derivative of left ventricular pressure.
Incidence (A) and duration (B) of ventricular fibrillation after  reperfusion Figure 1
Incidence (A) and duration (B) of ventricular fibrillation after 
reperfusion. * p < 0.05 vs. OLETF rats at 32 weeks of age, † p 
< 0.05 vs. LETO rats at 32 weeks of age.
I
n
c
i
d
e
n
c
e
 
o
f
 
V
e
n
t
r
i
c
u
l
a
r
 
F
i
b
r
i
l
l
a
t
i
o
n
 
(
%
)
0
20
40
60
80
100
16-L 16-O 32-L 32-O 32-LT 32-OT
D
u
r
a
t
i
o
n
 
o
f
 
V
e
n
t
r
i
c
u
l
a
r
 
F
i
b
r
i
l
l
a
t
i
o
n
 
(
s
e
c
)
0
200
400
600
800
1000
1200
1400
16-L 16-O 32-L 32-O 32-LT 32-OT
**
†
A
BCardiovascular Diabetology 2007, 6:17 http://www.cardiab.com/content/6/1/17
Page 5 of 7
(page number not for citation purposes)
Discussion
In the present study, a prolonged duration of reperfusion
arrhythmia was observed in hearts from OLETF rats at 32
weeks of age, in which obesity and hyperglycemia were
confirmed by OGTT results. Further, pH levels were lower
and proton production was significantly higher in the cor-
onary effluent of those rats as compared with age matched
LETO rats. In addition, the duration of reperfusion
arrhythmia was significantly shortened, while the
decrease in pH and increase in proton production were
significantly suppressed in coronary effluent samples fol-
lowing treatment with troglitazone in the hearts of those
OLETF rats.
In the present study, the plasma glucose level at 60 min
during OGTT was greater than 300 mg/dl in OLETF rat at
32 weeks of age, and the HbA1c level was also signifi-
cantly higher as compared to the age matched LETO rats.
According to our results as well as those of other studies
[8,11], OLETF rats at 32 weeks of age in the present study
were at the impaired glucose tolerance (IGT) stage. Dem-
onstrating IGT and obesity, these characteristics resem-
bled human type 2 DM at an early stage. The plasma
glucose levels after fasting and in the OGTT results, as well
as HbA1c and serum insulin levels, were improved in
OLETF rats at 32 weeks of age by treatment with troglita-
zone as in other reports [12].
There have been other studies on cardiac function in dia-
betic OLETF rats. Mizushige et al. [3] reported the occur-
rence of a left ventricular diastolic dysfunction in the
prediabetic stage of OLETF rat using doppler echocardiog-
raphy. Abe et al. [13] also reported occurrence of left ven-
tricular diastolic dysfunction in diabetic OLETF rats at 62–
66 weeks of age in experiments with isolated hearts,
though that dysfunction was not observed at 40–46 weeks
Changes in proton content in coronary effluent from LETO  and OLETF rats at 16 weeks of age (A) and 32 weeks of age  (B) Figure 4
Changes in proton content in coronary effluent from LETO 
and OLETF rats at 16 weeks of age (A) and 32 weeks of age 
(B). Closed circles show LETO rats, open circles show 
OLETF rats. * p < 0.05 vs. LETO rats.
Changes in pH of coronary effluent in troglitazone-treated  and non-treated LETO rats (A), and in troglitazone-treated  and non-treated OLETF rats (B) at 32 weeks of age Figure 3
Changes in pH of coronary effluent in troglitazone-treated 
and non-treated LETO rats (A), and in troglitazone-treated 
and non-treated OLETF rats (B) at 32 weeks of age. Closed 
circles show non-treated LETO rats, gray circles show trogli-
tazone-treated LETO rats, open circles show non-treated 
OLETF rats, bias circles show troglitazone-treated OLETF 
rats. * p < 0.05 vs. OLETF rats.
Changes in proton content in coronary effluent from troglita- zone-treated and non-treated LETO rats (A), and from trogl- itazone-treated and non-treated OLETF rats (B) at 32 weeks  of age Figure 5
Changes in proton content in coronary effluent from troglita-
zone-treated and non-treated LETO rats (A), and from trogl-
itazone-treated and non-treated OLETF rats (B) at 32 weeks 
of age. Closed circles show non-treated LETO rats, gray cir-
cles show troglitazone-treated LETO rats, open circles show 
non-treated OLETF rats, bias circles show troglitazone-
treated OLETF rats. * p < 0.05 vs. OLETF rats.Cardiovascular Diabetology 2007, 6:17 http://www.cardiab.com/content/6/1/17
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of age. Impaired cardiac contraction during working heart
perfusion in OLETF rats at 12 months of age [4] and an
impairement in vivo cardiac contraction in OLETF rats at
36 [14] and 62 [15] weeks of age have also been reported.
In the present study, the LV functional parameters before
ischemia did not differ between the LETO and OLETF rats
at 32 weeks of age. We considered that the discrepancies
between these reports may have been caused by the differ-
ent experimental methods and stage of diabetes in the ani-
mals. Meanwhile, one of the fatty obese rodents, JCR: LA-
cp rats have been reported to have a normal basal myocar-
dial function, while those animals also exhibited an
increased sensitivity to ischemic myocardial injury that
developed with advancing age [5]. The present results for
OLETF rat hearts are similar to those findings.
The pH values in coronary effluent did not drop dramati-
cally after inducing ischemia, in contrast to myocardial
intracellular pH levels measured in other studies of no-
flow ischemia [6,16]. In the present study, low-flow
ischemia was induced, which might be the reason for this
discrepancy. However, pH values decreased significantly
after 10 min of ischemia as compared with those before
ischemia in all groups (Figure 2 and 3). Additionally,
those decreases in pH values after 10 min of ischemia
(∆pH = 0.3–0.4) were similar to the results of other
reports with low-flow ischemia [16]. Thus, the most
important finding regarding cardiac metabolism in the
present study was exacerbated acidosis during ischemia in
the hearts of OLETF rats after the incidence of IGT. As
sources of acidosis during ischemia in hearts, anaerobic
glycolysis, CO2 production from respiration in mitochon-
dria, impairment in the oxygenation of NADH2, and the
effects of proton production cycle are well-known. We
previously reported higher levels of lactate production
during ischemia in the hearts of OLETF rats at 32 weeks of
age [17]. Thus, the findings in the present study may
mainly correlate with an acceleration of anaerobic glycol-
ysis during ischemia in the myocardium of OLETF rats at
that age. Anaerobic glycolysis is an important source of
ATP production, however, it causes increases in the accu-
mulation of acidotic metabolites and decreases in intrac-
ellular pH, and is also correlates with the severety of
myocardial damage. In addition, local acidosis leads to
alterations in electrical currents and electrophysiological
changes in cell membranes [18]. While, severe acidosis
and elevated proton production increase intracellular Na+
via Na+-H+ exchanger during ischemia in the myocar-
dium. Increased intracellular Na+ causes intracellular Ca2+
overload after reperfusion, and reperfusion arrhythmia
occurs [19]. Regarding these previous reports, exacerba-
tion of acidosis and increased proton production can be
correlated with prolonged duration of reperfusion
induced VF in the hearts of OLETF rats at 32 weeks of age.
Additionally, IGT improved, and exacerbation of acidosis
and an increase in proton production in the coronary
effluent were suppressed during ischemia at that age by
treatment with troglitazone. Moreover, the duration of
reperfusion induced VF was shortened simultaneously.
These results confirmed the correlation between impaired
glucose metabolism and increased sensitivity to ischemia
in the myocardium of OLETF rats after the incidence of
IGT. In ischemia-reperfusion experiments using sponta-
neous type 2 diabetic rodent hearts, impaired recovery of
cardiac function after reperfusion has been reported [4].
In a heart perfusion study conducted by Maddaford et al.
[5], ATP and glycogen contents in the insulin-resistant rat
myocardiums decreased significantly after ischemia-reper-
fusion, indicating acceleration of the consumption and
drying of stored energy. Sidell et al [6] reported a greater
loss of ATP and lactate production in the Zucker Fatty rat
hearts during ischemia, thus correlating to a lower recov-
ery in the contractile function during reperfusion. In the
only known report of reperfusion arrhythmia in sponta-
neous type 2 diabetic animal hearts, which utilized db/db
mice, an increase in the incidence and prolonged duration
of reperfusion arrhythmia were observed [7]. In that
study, a greater increase in intracellular Na+ was indicated
as the main cause of those conditions. As for ion homeos-
tasis, altered intracellular Ca2+ handling [20] and KATP cur-
rents [21] in spontaneous diabetic mouse myocytes have
been reported. These alterations also have possibility to
increase the incidence or prolong the duration of reper-
fusion arrhythmia. Thus, some metabolic mechanisms or
ion homeostasis apart from intracellular acidosis and pro-
ton efflux may correlate with increased sensitivity to
ischemia in hearts of OLETF rats at 32 weeks of age.
We also observed a shortening of the duration of reper-
fusion arrhythmia VF following treatment with troglita-
zone in the hearts of non-diabetic LETO rats at 32 weeks
of age. There was not a significant difference in pH level
and proton efflux between the treated and non-treated
groups. Then, some mechanisms apart from improve-
ment of glucose metabolism might shorten the duration
of the reperfusion induced VF in the hearts of OLETF rats
at 32 weeks of age treated with troglitazone. In fact, an
improvement in the recovery of cardiac function after
ischemia has been reported in non-diabetic pig hearts
treated with troglitazone for a long time [22]. However,
after treatment with troglitazone, the incidence of VF did
not improve in the hearts of LETO rats at 32 weeks of age,
whereas that in the hearts of age matched OLETF rats
tended to be improved (p = 0.10). These results demon-
strate that suppression of alteration in glucose metabo-
lism according to the incidence of IGT in myocardium
should be the main mechanism improving the exacerba-
tion of reperfusion injury by treatment with troglitazone
in OLETF rat. Recent clinical trials have revealed that thia-
zolinediones provide a better prognosis in diabeticPublish with BioMed Central    and   every 
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patients with coronary heart disease [23]. However, the
effects of thiazolidinediones, including troglitazone, on
the heart have not been well clarified and additional
investigations are required.
Conclusion
Sensitivity to ischemia increased after the incidence of
impaired glucose tolerance in the hearts of OLETF rats,
which improved by the treatment with troglitazone. We
concluded that exacerbation of acidosis through altered
glucose metabolism during ischemia is one of the causes
of this phenomenon in diabetic OLETF rats.
Abbreviations
DM, diabetes mellitus; OGTT, oral glucose tolerance test;
VF, ventricular fibrillation.
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